Adimab LLC.

Overview

Unlocking the Potential of Antibody Discovery: Adimab LLC.

Adimab LLC., founded in 2007 by Dr. Tillman Gerngross, Dr. Dane Wittrup, and Errik Anderson, is revolutionizing the field of antibody discovery with its cutting-edge technology and innovative approach. With a team of world-class experts in yeast biotechnology and financial innovation, Adimab has developed the most advanced and comprehensive antibody discovery platform in the pharmaceutical industry.

Led by Dr. Gerngross, a renowned professor at Dartmouth College and the co-founder of multiple successful biotechnology companies, Adimab is at the forefront of engineering yeast for the production of human glycoproteins. Dr. Wittrup, a distinguished professor at MIT and a pioneer in yeast surface display, has played a pivotal role in the discovery and maturation of antibody fragments. Mr. Anderson, a seasoned entrepreneur and co-founder of several technology companies, brings invaluable expertise to the team.

Adimab's antibody discovery technology is unrivaled in terms of quality and speed, offering a streamlined process from target identification to therapeutic molecule development. This groundbreaking approach has attracted top-tier pharmaceutical companies as well as highly innovative biotechnology firms that share Adimab's passion for delivering best-in-class molecules to patients expeditiously.

One of the remarkable achievements of Adimab's technology is its collaboration with Merrimack, where a panel of antibodies meeting desired project criteria was discovered within a few months. This remarkable feat enabled Merrimack to file an Investigational New Drug (IND) application within 18 months and administer the first dose to a patient just two years after initiating the project. Such a timeline is unprecedented in the realm of de novo drug discovery, showcasing the unparalleled speed and efficiency of Adimab's platform.

Working at Adimab offers employees a unique opportunity to be part of a dynamic and pioneering company that is transforming the pharmaceutical industry. The company's commitment to excellence and innovation is evident in its team of world-class scientists and entrepreneurs, who constantly push the boundaries of what is possible in antibody discovery.

Employees at Adimab are exposed to a stimulating and collaborative work environment, where they have the chance to work alongside industry leaders and contribute to groundbreaking research. The company's emphasis on long-term value creation ensures that employees are not only involved in cutting-edge projects but also have the opportunity to make a lasting impact on patient care.

Furthermore, Adimab's partnerships with top-tier pharmaceutical companies and innovative biotechnology firms provide employees with unparalleled networking opportunities and exposure to a diverse range of projects. This exposure allows employees to expand their knowledge and expertise, fostering professional growth and development.

Adimab's commitment to bringing best-in-class molecules to patients quickly is not only a testament to its dedication to improving healthcare but also a source of inspiration for employees. Being part of a company that prioritizes patient well-being and strives to make a difference in people's lives can be incredibly fulfilling and motivating.

In conclusion, Adimab LLC. is a trailblazer in the field of antibody discovery, driven by a team of world-class experts and a commitment to excellence. The company's unrivaled technology and innovative approach have attracted top-tier pharmaceutical companies and biotechnology firms, offering employees a unique opportunity to be part of groundbreaking research and make a lasting impact on patient care. Working at Adimab provides a stimulating and collaborative environment, fostering professional growth and development. Join Adimab and unlock the potential of antibody discovery.